ARK Reports 6.67% Personalis Stake With Sole Voting Authority Over 7.1 Million Shares
Catherine D. Wood reported shared voting authority over the same position in the cancer-testing company.
ARK Investment Management reported a 6.67% stake in Personalis, which provides advanced cancer genomic testing, in an SEC ownership amendment filed Friday. The investment adviser reported 7,119,390 common shares—about 7.1 million—with sole authority to vote them, covering holdings as of September 30.
One Position, Different Voting Powers
Catherine D. Wood, ARK's chief executive officer and chief investment officer, was the other reporting person. She reported shared voting authority over the same shares; the position appears under both names and represents the same 6.67% of the common-stock class.
ARK also reported sole authority to sell or otherwise dispose of the shares, while Wood reported shared authority over those decisions.
ARK identified ARK Genomic Revolution ETF, a fund holding an interest in the reported securities, as the exception to its statement that no client had an interest exceeding 5%.
The adviser certified that it held the securities as part of its regular business, without a purpose of changing or influencing Personalis's control. The disclosure was a passive ownership amendment.
Cancer Testing And Concentrated Fund Holdings
Personalis's tests help physicians identify cancer that remains or returns, track treatment response and choose therapies. Pharmaceutical companies use its services to discover biological markers, conduct research and support clinical trials.
The company also sequences the protein-coding portions of DNA for other diagnostic companies and entire genomes for population-sequencing initiatives. Its customers span drugmakers, diagnostic businesses, universities, nonprofits, government entities and cancer patients, served through a small direct sales team.
Personalis operates a single business segment and performs testing at its laboratory within its 100,000-square-foot Fremont, California, headquarters. In 2025, U.S. customers contributed 90% of revenue, Europe 9% and other markets 1%. Moderna accounted for 22% of revenue that year.
ARK's ETFs take concentrated positions in small- and mid-cap companies, frequently crossing ownership-reporting thresholds. Those holdings have produced about 170 ownership schedules over two years.
Personalis had a market value of $1.7 billion in Friday trading as of 12:53 p.m. ET.
For Personalis holders, ARK's reported position carries voting authority over 6.67% of the common-stock class.
Sources
- SCHEDULE 13G/A — ARK Investment Management LLC re: Personalis, Inc. (PSNL) — SEC EDGAR
- SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1 — SEC EDGAR